Tag: biologics
-
Two Jabs a Year: The Life-Changing Asthma Drug Depemokimab
New Hope for Asthma Sufferers: Depemokimab reduces treatment burden In a breakthrough that could redefine how asthma is managed, scientists are reporting that depemokimab, a biologic drug, may offer life-changing relief with just two injections annually. The trials, led by researchers including Ian Pavord of the University of Oxford, position depemokimab as a potent alternative…
-
A Breakthrough: Two-Yearly Injections Could Transform Asthma Care
Overview: A New Frontier in Asthma Treatment Researchers are heralding a potential turning point for asthma management with depemokimab, a biologic therapy that may reduce the need for frequent injections. Unlike traditional daily or monthly biologics, this emerging approach could halve the number of injections required, delivering a dose twice per year. The development has…
-
Depemokimab: A New Era for Asthma with Just Two Annual Injections
Introduction: A potential turning point in asthma care New research into depemokimab, a targeted biologic for asthma, is stirring cautious optimism in clinics and among patients who live with the daily challenges of the condition. Led by Ian Pavord, a professor of respiratory medicine at the University of Oxford, the trials position depemokimab as a…
-
ESMO Therapeutic Landscapes: Toxicity and Safety Management of Multispecific Antibodies and Immune-Cell Engagers
Overview of ESMO Therapeutic Landscapes 2026 The ESMO Therapeutic Landscapes webinar series returns in 2026 with a focused session on the toxicity and safety considerations surrounding multispecific antibodies and immune-cell engagers. Scheduled for February 18, 2026, this technical program brings together hematology-oncology clinicians, translational scientists, and pharmacovigilance experts to examine the real-world challenges of next-generation…
-
ESMO Therapeutic Landscapes: Toxicity of Multispecific Antibodies and Immune-Cell Engagers
Overview ESMO Therapeutic Landscapes 2026 is set to explore the safety profiles and clinical management of next-generation biologics, with a focused session on the toxicity of multispecific antibodies and immune-cell engagers. Scheduled for February 18, 2026, this technical webinar brings together leading oncologists, immunologists, and translational researchers to dissect risk factors, mechanism-based toxicities, and practical…
-
Multiple Innovent Biomedicine Pipeline Results Highlight at 2025 ACR Annual Meeting
Overview: Innovent showcases General Biomedicine Pipeline at the 2025 ACR Annual Meeting Innovent Biologics, a global biopharmaceutical leader, presented multiple research results from its General Biomedicine Pipeline at the 2025 American College of Rheumatology (ACR) Annual Meeting and related events. While the conference is renowned for rheumatology and autoimmune disease breakthroughs, Innovent emphasized its expanding…